Basic Information
DYSPORT FOR INJECTION 300u/vial
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN15238P
May 16, 2017
Prescription Only
Therapeutic
SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
June 4, 2025
XM03AX01
Company Information
Active Ingredients
Strength: 300u/vial
Detailed Information
Contraindications
**4.3 Contraindications** Known hypersensitivity to the active substance or to any excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** Dysport is indicated for symptomatic treatment of focal spasticity of: - Upper limbs in adults - Lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury (TBI) - Dynamic equinus foot deformity in ambulant paediatric cerebral palsy patients, two years of age or older - Upper limbs paediatric cerebral palsy patients, two years of age or older Dysport is indicated in adults for symptomatic treatment of: - Spasmodic torticollis - Blepharospasm - Hemifacial spasm - Axillary hyperhidrosis Dysport is indicated for the temporary improvement in the appearance of moderate to severe: - Glabellar lines (vertical lines between the eyebrows) seen at maximum frown and/or - Lateral canthal lines (crow's feet lines) seen at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.